ATYR PHARMA INC(ATYR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATYR ATYR PHARMA INC

Trading 03-28 13:34:59 EDT

3.09

-0.17

-5.21%

High3.26	Low3.09	Vol589.66K
Open3.25	D1 Closing3.26	Amplitude5.21%
Mkt Cap274.57M	Tradable Cap253.28M	Total Shares88.86M
T/O1.86M	T/O Rate0.72%	Tradable Shares81.97M
P/B3.92	ROE-79.88%	EPS-0.86
52wk High4.66	52wk Low1.42	P/E-3.58
Dividend0.00	Div.Yield0.00	ROA-39.03%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ATYR","market":"US","secType":"STK","nameCN":"ATYR PHARMA INC","latestPrice":3.09,"timestamp":1743183281276,"preClose":3.26,"halted":0,"volume":589654,"delay":0,"floatShares":81968300,"shares":88858612,"eps":-0.862131,"marketStatus":"Trading","change":-0.17,"latestTime":"03-28 13:34:55 EDT","open":3.25,"high":3.26,"low":3.09,"amount":1858729.8046174,"amplitude":0.052147,"askPrice":3.1,"askSize":2319,"bidPrice":3.09,"bidSize":710,"shortable":3,"etf":0,"ttmEps":-0.862131,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743192000000},"marketStatusCode":2,"adr":0,"listingDate":1430971200000,"exchange":"NASDAQ","adjPreClose":3.26,"preHourTrading":{"tag":"盘前","latestPrice":3.3,"preClose":3.26,"latestTime":"09:27 EDT","volume":760,"amount":2535.476128,"timestamp":1743168470036},"postHourTrading":{"tag":"盘后","latestPrice":3.23,"preClose":3.26,"latestTime":"18:49 EDT","volume":1964,"amount":6433.9913,"timestamp":1743115757041},"volumeRatio":0.849988,"impliedVol":2.0873,"impliedVolPercentile":0.7549},"requestUrl":"/m/hq/s/ATYR","defaultTab":"news","newsList":[{"id":"2522553939","title":"BRIEF-ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522553939","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522553939?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:00","pubTimestamp":1743105643,"startTime":"0","endTime":"0","summary":"BRIEF-ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)March 27 (Reuters) - aTyr Pharma Inc ATYR.O:ATYR PHARMA ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)Source text: ID:nGNX24vnkbFurther company coverage: ATYR.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA5W1Q5Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2522539363","title":"aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522539363","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522539363?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:00","pubTimestamp":1743105600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA5W1Q5Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2522687425","title":"BRIEF-aTyr Pharma Announces The Appointment Of Dalia R. Rayes As Head Of Commercial, Global Efzofitimod Franchise","url":"https://stock-news.laohu8.com/highlight/detail?id=2522687425","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522687425?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 20:07","pubTimestamp":1742990835,"startTime":"0","endTime":"0","summary":"BRIEF-aTyr Pharma Announces The Appointment Of Dalia R. Rayes As Head Of Commercial, Global Efzofitimod FranchiseMarch 26  - aTyr Pharma Inc ATYR.O:ATYR PHARMA ANNOUNCES THE APPOINTMENT OF DALIA R. RAYES AS HEAD OF COMMERCIAL, GLOBAL EFZOFITIMOD FRANCHISESource text: ID:nGNX59kDFurther company coverage: ATYR.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA1CV1J7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2522871717","title":"aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise","url":"https://stock-news.laohu8.com/highlight/detail?id=2522871717","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522871717?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 20:00","pubTimestamp":1742990403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA1CV1J7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2522889808","title":"aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise","url":"https://stock-news.laohu8.com/highlight/detail?id=2522889808","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522889808?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 20:00","pubTimestamp":1742990400,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 26, 2025  -- aTyr Pharma, Inc.  , a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise. Ms. Rayes brings over 25 years of experience building and leading commercial organizations at biotechnology and pharmaceutical companies, including leading rare disease product launches. She will serve as a member of the Company’s executive leadership team, overseeing global commercial strategy and operations for the efzofitimod program in interstitial lung disease , including its lead indication in pulmonary sarcoidosis.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atyr-pharma-announces-appointment-dalia-120000781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2519877861","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcus Biosciences (RCUS), aTyr Pharma (ATYR) and Lyra Therapeutics (LYRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2519877861","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519877861?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 19:00","pubTimestamp":1741950059,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arcus Biosciences (RCUS – Research Report), aTyr P...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-arcus-biosciences-rcus-atyr-pharma-atyr-and-lyra-therapeutics-lyra?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-arcus-biosciences-rcus-atyr-pharma-atyr-and-lyra-therapeutics-lyra?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","LYRA","ATYR","BK4139","BK4007","RCUS","BK4137"],"gpt_icon":0},{"id":"2519799872","title":"aTyr Pharma Price Target Maintained With a $35.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2519799872","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519799872?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 18:59","pubTimestamp":1741949940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ATYR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 14, 2025 06:59 ET (10:59 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR"],"gpt_icon":0},{"id":"2519427168","title":"aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2519427168","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519427168?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 15:11","pubTimestamp":1741936271,"startTime":"0","endTime":"0","summary":"Cash and Investments: $75.1 million at the end of 2024.ATM Offering Proceeds: Approximately $18.8 million raised subsequent to Q4 2024.Collaboration and License Revenue: $0.2 million for 2024 from the Kurin Agreement.Total Revenue from Kurin Agreement: Over $20 million received to date, with potential for up to $155 million in additional milestone payments.Research and Development Expenses: $54.4 million for the year ended 2024.General and Administrative Expenses: $13.8 million for the year ended 2024.Cash Runway: Expected to fund operations through one year following the phase 3 FSOfi readout.GuruFocus has detected 5 Warning Signs with ATYR.For the complete transcript of the earnings call, please refer to the full earnings call transcript.aTyr Pharma Inc  has published a manuscript in Science Translational Medicine, validating the mechanism of action of epsofitamo and reinforcing its potential application in chronic inflammatory conditions.The company has a strong cash position, endin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atyr-pharma-inc-atyr-q4-071111439.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ATYR"],"gpt_icon":0},{"id":"2519699958","title":"aTyr Pharma Q4 EPS $(0.18) Beats $(0.23) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2519699958","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519699958?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 04:11","pubTimestamp":1741896669,"startTime":"0","endTime":"0","summary":"aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.23) by 21.74 percent. This is a 28 percent increase over losses of $(0.25) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44315888/atyr-pharma-q4-eps-0-18-beats-0-23-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"aTyr Pharma Q4 EPS $(0.18) Beats $(0.23) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR"],"gpt_icon":0},{"id":"2519866726","title":"Press Release: aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2519866726","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519866726?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 04:01","pubTimestamp":1741896060,"startTime":"0","endTime":"0","summary":"Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT study reinforces its favorable safety profile.\"2024 was an important year for aTyr, as we completed enrollment in our global pivotal Phase 3 EFZO-FIT study, which is the largest interventional study ever to be conducted in pulmonary sarcoidosis, a disease where incidence and prevalence are rising yet there are still limited treatment options,\" said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. \"The stage is set for 2025 to be a potential milestone year as we look toward reporting topline data for EFZO-FIT in the third quarter. Leading into this pivotal readout, we are very pleased with the execution of the study to date and the continued favorable safety profile demonstrated for efzofitimod, including our most recent positive DSMB review, which recommended the study continue ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","BK4585","ATYR","BK4528","BK4555","BK4139","ATS","03160","SAP","BK4604","TM","BK4588","BK4613","BK4023","BK4099"],"gpt_icon":1},{"id":"2518719987","title":"aTyr Pharma Inc  expected to post a loss of 23 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2518719987","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518719987?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 04:09","pubTimestamp":1741723746,"startTime":"0","endTime":"0","summary":"aTyr Pharma Inc  expected to post a loss of23cents a share - Earnings Preview aTyr Pharma Inc ATYR.OQ ATYR.O is expected to show a rise in quarterly revenue when it reports  results on March 13 for th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nL8N3PU28I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR"],"gpt_icon":0},{"id":"2517612118","title":"aTyr Pharma Announces Fourth Positive Dsmb Review for Efzofitimod in Phase 3 Efzo-Fit™ Study in Pulmonary Sarcoidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2517612118","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517612118?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 05:02","pubTimestamp":1741294946,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PP1KU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2516493676","title":"aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516493676","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516493676?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 21:00","pubTimestamp":1741093200,"startTime":"0","endTime":"0","summary":"Management to host conference call and webcast on March 13th at 5:00 pm EDT / 2:00 pm PDT. SAN DIEGO, March 04, 2025  -- aTyr Pharma, Inc. , a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2024 financial results and provide a corporate update after the market close on Thursday, March 13, 2025. Management will host a conference call and webcast to review the results and provide an operational update.Participants who wish to join the conference call by telephone must register at the above dial-in registration link in order to receive the dial-in number and a personalized PIN code that will be required to access the call. Participants may join the live webcast by accessing it at the above webcast registration link on the aTyr Events page. For more information or questions, please contact aTyr’s investor relations team a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atyr-pharma-webcast-conference-call-130000373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ATYR"],"gpt_icon":1},{"id":"2512592671","title":"aTyr Pharma Initiated at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2512592671","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512592671?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 20:13","pubTimestamp":1739880780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ATYR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2025 07:13 ET (12:13 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR"],"gpt_icon":0},{"id":"2512815953","title":"Leerink Partners Initiates Coverage on aTyr Pharma With Outperform Rating, $16 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2512815953","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512815953?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 20:09","pubTimestamp":1739880547,"startTime":"0","endTime":"0","summary":"aTyr Pharma (ATYR) has an average rating of Buy and mean price target of $20, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATYR"],"gpt_icon":0},{"id":"2512715302","title":"aTyr Pharma initiated with an Outperform at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2512715302","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512715302?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 19:18","pubTimestamp":1739877483,"startTime":"0","endTime":"0","summary":"Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong conf...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atyr-pharma-initiated-with-an-outperform-at-leerink?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atyr-pharma-initiated-with-an-outperform-at-leerink?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2512153017","title":"Buy Rating on aTyr Pharma Driven by Promising Efzofitimod Phase 3 Study Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2512153017","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512153017?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 19:17","pubTimestamp":1739877464,"startTime":"0","endTime":"0","summary":"aTyr Pharma (ATYR) has received a new Buy rating, initiated by Leerink Partners analyst, Faisal Khurshid. Faisal Khurshid has given his Buy rating ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-on-atyr-pharma-driven-by-promising-efzofitimod-phase-3-study-prospects?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-on-atyr-pharma-driven-by-promising-efzofitimod-phase-3-study-prospects?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2512715829","title":"aTyr Pharma Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $16","url":"https://stock-news.laohu8.com/highlight/detail?id=2512715829","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512715829?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 19:04","pubTimestamp":1739876691,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250218:nFWN3P90AR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2507671393","title":"Here's Why We're Watching aTyr Pharma's (NASDAQ:ATYR) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2507671393","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507671393?lang=en_us&edition=full_marsco","pubTime":"2025-01-31 02:04","pubTimestamp":1738260249,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, aTyr Pharma  shareholders have done very well over the last year, with the share price soaring by 128%. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.So notwithstanding the buoyant share price, we think it's well worth asking whether aTyr Pharma's cash burn is too risky. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-were-watching-atyr-180409736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","USAW.SI","IE00BGHQF748.EUR","LU2095319765.USD","QLD","BK4112","QID","TSYW.SI","NDAQ","TQQQ","PSQ","NVIW.SI","LU2210149790.SGD","MNQmain","USJW.SI","NQmain","LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4585","BK4588","IE00BKPKM429.USD","ATYR","SQQQ","BK4139"],"gpt_icon":1},{"id":"2502845856","title":"Several Insiders Invested In aTyr Pharma Flagging Positive News","url":"https://stock-news.laohu8.com/highlight/detail?id=2502845856","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502845856?lang=en_us&edition=full_marsco","pubTime":"2025-01-10 18:20","pubTimestamp":1736504400,"startTime":"0","endTime":"0","summary":"When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase stock, like in aTyr Pharma, Inc.'s  instance, it's good news for shareholders.Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.The Last 12 Months Of Insider Transactions At aTyr Pharma. Over the last year, we can see that the biggest insider purchase was by Independent Director Paul Schimmel for US$185k worth of shares, at about US$1.93 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$3.74. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.While aTyr Pharma insiders bought shares during the last year, they didn't sell. The chart below shows insider transactions  over the last year. If you want to know exactly who sol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/several-insiders-invested-atyr-pharma-102000721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ATYR","BK4139"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.atyrpharma.com","stockEarnings":[{"period":"1week","weight":-0.133},{"period":"1month","weight":-0.1398},{"period":"3month","weight":-0.1283},{"period":"6month","weight":0.8418},{"period":"1year","weight":0.63},{"period":"ytd","weight":-0.0994}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":-0.0457},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0077},{"period":"1year","weight":0.0839},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.7,"avgChangeRate":0.026814},{"month":2,"riseRate":0.4,"avgChangeRate":-0.021771},{"month":3,"riseRate":0.4,"avgChangeRate":-0.050773},{"month":4,"riseRate":0.222222,"avgChangeRate":-0.052458},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.096577},{"month":6,"riseRate":0.5,"avgChangeRate":-0.034182},{"month":7,"riseRate":0.5,"avgChangeRate":0.005168},{"month":8,"riseRate":0.1,"avgChangeRate":-0.079736},{"month":9,"riseRate":0.5,"avgChangeRate":0.102256},{"month":10,"riseRate":0.3,"avgChangeRate":0.01241},{"month":11,"riseRate":0.6,"avgChangeRate":0.036606},{"month":12,"riseRate":0.4,"avgChangeRate":-0.067625}],"exchange":"NASDAQ","name":"ATYR PHARMA INC","nameEN":"ATYR PHARMA INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ATYR PHARMA INC(ATYR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ATYR PHARMA INC(ATYR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ATYR PHARMA INC,ATYR,ATYR PHARMA INC股票,ATYR PHARMA INC股票老虎,ATYR PHARMA INC股票老虎国际,ATYR PHARMA INC行情,ATYR PHARMA INC股票行情,ATYR PHARMA INC股价,ATYR PHARMA INC股市,ATYR PHARMA INC股票价格,ATYR PHARMA INC股票交易,ATYR PHARMA INC股票购买,ATYR PHARMA INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ATYR PHARMA INC(ATYR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ATYR PHARMA INC(ATYR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction